Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171535 | 0.89 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL27828545 | 0.85 | PTGS2 (0.42) | PTGDR2JAK2JAK1TYK2JAK3 | |
| SCHEMBL709951 | 0.81 | PTGDR2 (0.44) | PTGDR2PTGS2 | |
| SCHEMBL711075 | 0.79 | PTGDR2 (0.43) | PTGDR2PTGS2 | |
| SCHEMBL707962 | 0.78 | PTGDR2 (0.42) | PTGDR2PTGS2 | |
| SCHEMBL2171906 | 0.75 | HSP90AB1 (0.50) | MEN1KMT2A | |
| SCHEMBL710381 | 0.73 | PTGDR2 (0.44) | PTGDR2MEN1KMT2AEGFR | |
| SCHEMBL709863 | 0.73 | PTGDR2 (0.55) | PTGDR2PTGS2 | |
| SCHEMBL2175362 | 0.73 | PTGDR2 (0.39) | PTGDR2 | |
| SCHEMBL2171888 | 0.72 | MMP9 (0.44) | PTGDR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346819-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 49/4885JAK2 2448/4885JAK1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.